Pharmaceutical Executive Daily: Wegovy Shows Potential to Treat MASH Patients
Nov 11, 09:41 PM
Share
Subscribe
In today’s Pharmaceutical Executive Daily, we report on new data showing Wegovy’s potential to reduce liver injury in patients with MASH, Eli Lilly’s latest strategic collaborations in gene therapy, and Novo Nordisk’s decision not to increase its acquisition offer for Metsera following Pfizer’s entry.